News
31 March 2020

EIB finances AM-Pharma's development of acute kidney injury treatment

In:
Infrastructure
Region:
Europe

The EIB and Utrecht-based AM-Pharma have signed a €24 million financing agreement. The funds will be used to accelerate the development of the clinical stage biopharmaceutical company’s recombinant alkaline phosphatase enzyme, which is used to treat acute kidney injury (AKI). The...

Exclusive subscriber content…

If you are a TXF subscriber, please login to continue reading

Login

Not yet a subscriber? Join us today to continue accessing content without any restrictions

View our subscription options

Or to request access to TXF Intelligence contact us

Request Access

You might also like


Perspective
20 June 2025

Oil & gas dealmaking resurgent amid geopolitical strife

A new report into bank funding for the fossil fuel industry has highlighted a resurgence in dealmaking for oil & gas firms. ECAs may have stepped away, but regardless...

Video
26 June 2025

10 minutes with Abdulrahman Al Sowaidi, CEO, QDB

TXF talks to Abdulrahman Al Sowaidi, CEO of Qatar Development Bank (QDB), at the Exile Global 2025 event, discussing topics such as QDB's multifaceted product offering and its...